RADNOR, Pa., May 14, 2018 (GLOBE NEWSWIRE) -- Kaskela Law LLC alerts Esperion Therapeutics, Inc. (NASDAQ:ESPR) (“Esperion” or the “Company”) shareholders that a class action lawsuit has been filed on behalf of purchasers of the Company’s securities between February 22, 2017 and May 1, 2018, inclusive (the “Class Period”).

DEADLINE ALERT: Investors who purchased Esperion securities during the Class Period may, no later than July 6, 2018, seek to be appointed as a lead plaintiff representative of the investor class. Esperion investors are encouraged to visit www.kaskelalaw.com/case/esperion-therapeutics to receive additional information about this action prior to the deadline.

On May 2, 2018, Esperion announced results from its second pivotal Phase 3 study for its cholesterol-lowering medication. Esperion reported that although the trial met the primary endpoint of safety and tolerability, and the key efficacy endpoint, there were 13 deaths in the treatment group compared to only two in the control group.

Following this news, shares of the Company’s stock declined $24.75 per share, or over 35%, to close on May 2, 2018 at $45.75.

The shareholder class action complaint alleges, among other things, that Esperion and certain of its senior executive officers made false and misleading statements and/or failed to disclose to investors that the Company’s cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death. The complaint further alleges that, as a result of the foregoing, investors purchased Esperion’s securities at artificially inflated prices during the Class Period and sustained investment losses following the Company’s May 2, 2018 disclosure.

Esperion investors are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585 or (888) 715 – 1740, or via www.kaskelalaw.com/case/esperion-therapeutics, to discuss their legal rights and options with respect to this action prior to July 6, 2018.

Kaskela Law LLC exclusively prosecutes shareholder actions in state and federal courts throughout the country on behalf of investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

CONTACT:

KASKELA LAW LLCD. Seamus Kaskela, Esq.201 King of Prussia RoadSuite 650Radnor, PA 19087 (484) 258 – 1585 (888) 715 – 1740 skaskela@kaskelalaw.comwww.kaskelalaw.com